دورية أكاديمية
The HFA-PEFF score identifies 'early-HFpEF' phenogroups associated with distinct biomarker profiles.
العنوان: | The HFA-PEFF score identifies 'early-HFpEF' phenogroups associated with distinct biomarker profiles. |
---|---|
المؤلفون: | Henkens MTHM; Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.; Netherlands Heart Institute (NLHI), Utrecht, The Netherlands., van Ommen AM; Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Remmelzwaal S; Department of Epidemiology and Data Science, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Valstar GB; Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Wang P; Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands., Verdonschot JAJ; Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands., Hazebroek MR; Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands., Hofstra L; Cardiology Centers of the Netherlands, Utrecht, The Netherlands., van Empel VPM; Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands., Beulens JWJ; Department of Epidemiology and Data Science, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., den Ruijter HM; Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Heymans SRB; Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.; Department of Cardiovascular Research, University of Leuven, Leuven, Belgium. |
المصدر: | ESC heart failure [ESC Heart Fail] 2022 Jun; Vol. 9 (3), pp. 2032-2036. Date of Electronic Publication: 2022 Mar 17. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [Oxford] : John Wiley & Sons Ltd on behalf of the European Society of Cardiology, [2014]- |
مواضيع طبية MeSH: | Heart Failure*/diagnosis , Somatomedins*, Biomarkers ; Humans ; Matrix Metalloproteinase 2 ; Middle Aged ; Pilot Projects ; Stroke Volume ; Ventricular Function, Left |
مستخلص: | Aims: The HFA-PEFF score was developed to optimize diagnosis and to aid in early recognition of heart failure (HF) with preserved ejection fraction (HFpEF) in patients who present with HF-like symptoms. Recognizing early-HFpEF phenogroups is essential to better understand progression towards overt HFpEF and pave the way for early intervention and treatment. Whether the HFA-PEFF domain scores can identify 'early-HFpEF' phenogroups remains unknown. The aims of this pilot study are to (i) identify distinct phenogroups by cluster analysis of HFA-PEFF domain scores in subjects that present with HF-like symptoms and (ii) study whether these phenogroups may be associated with distinct blood proteome profiles. Methods and Results: Subjects referred to the Cardiology Centers of the Netherlands, location Utrecht, with non-acute possibly cardiac-related symptoms (such as dyspnoea or fatigue) were prospectively enrolled in the HELPFul cohort (N = 507) and were included in the current analysis. Inclusion criteria for this study were (i) age ≥ 45 years and (ii) a left ventricular ejection fraction (LVEF) ≥ 50%, in the absence of a history of HF, coronary artery disease, congenital heart disease, or any previous cardiac interventions. Multinominal-based clustering with latent class model using the HFA-PEFF domain scores (functional, structural, and biomarker scores) as input was used to detect distinct phenotypic clusters. For each bootstrapping run, the 92 Olink proteins were analysed for their association with the identified phenogroups. Four distinct phenogroups were identified in the current analysis (validated by bootstrapping 1000×): (i) no left ventricular diastolic dysfunction (no LVDD, N = 102); (ii) LVDD with functional left ventricular (LV) abnormalities (N = 204); (iii) LVDD with functional and structural LV abnormalities (N = 204); and (iv) LVDD with functional and structural LV abnormalities and elevated BNP (N = 107). The HFA-PEFF total score risk categories significantly differed between the phenogroups (P < 0.001), with an increase of the HFA-PEFF score from Phenogroup 1 to 4 (low/intermediate/high HFA-PEFF risk score: Phenogroup 1: 88%/12%/0%; Phenogroup 2: 9%/91%/0%; Phenogroup 3: 0%/92%/8%; Phenogroup 4: 5%/83%/12%). Thirty-two out of the 92 Olink protein biomarkers significantly differed among the phenogroups. The top eight biomarkers-N-terminal prohormone brain natriuretic peptide, growth differentiation factor-15, matrix metalloproteinase-2, osteoprotegerin, tissue inhibitor of metalloproteinase-4, chitinase-3-like protein 1, insulin-like growth factor-binding protein 2, and insulin-like growth factor-binding protein 7-are mainly involved in inflammation and extracellular matrix remodelling, which are currently proposed key processes in HFpEF pathophysiology. Conclusions: This study identified distinct phenogroups by using the HFA-PEFF domain scores in ambulant subjects referred for HF-like symptoms. The newly identified phenogroups accompanied by their circulating biomarkers profile might aid in a better understanding of the pathophysiological processes involved during the early stages of the HFpEF syndrome. (© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.) |
References: | Nat Rev Cardiol. 2016 Jun;13(6):368-78. (PMID: 26935038) Nat Rev Cardiol. 2021 Jun;18(6):400-423. (PMID: 33432192) BMJ Open. 2019 Jun 5;9(6):e028408. (PMID: 31171553) Nat Rev Cardiol. 2017 Oct;14(10):591-602. (PMID: 28492288) Eur J Heart Fail. 2020 Sep;22(9):1586-1597. (PMID: 32592317) Eur Heart J. 2019 Oct 21;40(40):3297-3317. (PMID: 31504452) Circulation. 2018 Aug 28;138(9):861-870. (PMID: 29792299) Circ Heart Fail. 2019 May;12(5):e005897. (PMID: 31104495) ESC Heart Fail. 2022 Jun;9(3):2032-2036. (PMID: 35301820) |
فهرسة مساهمة: | Keywords: HFA-PEFF; HFpEF; Left ventricular diastolic dysfunction; biomarkers |
المشرفين على المادة: | 0 (Biomarkers) 0 (Somatomedins) EC 3.4.24.24 (Matrix Metalloproteinase 2) |
تواريخ الأحداث: | Date Created: 20220318 Date Completed: 20220505 Latest Revision: 20230916 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC9065816 |
DOI: | 10.1002/ehf2.13861 |
PMID: | 35301820 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2055-5822 |
---|---|
DOI: | 10.1002/ehf2.13861 |